Biotech startup redefining cancer screening, the company Melbourne needs to know about this month

Tucked away in a converted warehouse on Bridge Road in Cremorne, a Melbourne biotech startup is quietly reshaping how oncologists detect cancer in its earliest stages. Precision Genomics Melbourne (PGM), founded in 2021 by former researchers from the Garvan Institute, has just closed a Series B funding round that values the company at over $180 million—a significant milestone for Victoria's innovation ecosystem.

The company's core innovation centres on an AI-powered blood test capable of detecting circulating tumour DNA with 94 per cent accuracy, sometimes months before traditional imaging methods catch malignancy. For a nation where colorectal and breast cancers remain leading causes of death, the implications are profound.

"Early detection changes survival rates dramatically," says the technology's lead developer, speaking to the clinical impact rather than making specific claims about market disruption. What's clear is that PGM's approach addresses a genuine gap. Australia's cancer survival rates, while among the world's best, still lag Nordic countries where earlier intervention protocols are standard.

The $47 million raise—led by Asian venture capital firms with existing portfolios in Singapore and Tokyo—signals confidence in the company's ability to scale beyond Australia. PGM has already partnered with three major pathology networks across Victoria, including facilities in Footscray and Box Hill, enabling preliminary trials on over 12,000 patient samples.

What makes PGM notable isn't just the science. The company exemplifies Melbourne's evolving competitive advantage in precision medicine. Unlike Sydney's fintech dominance or Brisbane's resources-tech focus, Melbourne's innovation district—spanning Cremorne, Southbank, and the emerging precinct around the Docklands—has increasingly specialised in health technology. The city now hosts over 340 biotech and medtech companies, employing approximately 8,200 people directly.

The Cremorne location itself reflects this trend. What were textile factories a decade ago now house incubators, research labs, and startup offices. Nearby, the Baker Heart and Diabetes Institute, the Walter and Eliza Hall Institute, and the Olivia Newton-John Cancer Research Institute provide research partnerships that many biotech hubs globally would envy.

PGM's success also matters for Victoria's post-pandemic economic strategy. Life sciences investment across Australia hit $2.1 billion in 2025, but Victoria captured just 31 per cent—trailing New South Wales. Companies like PGM that achieve genuine scale could shift that calculation meaningfully.

The company plans to hire 85 additional staff across Melbourne by December, with particular focus on AI engineering and regulatory affairs roles. For the city's ambitions as a global innovation hub, that's exactly the kind of momentum worth monitoring.

This article was compiled by AI from the sources linked above and screened before publishing. See our editorial standards.